Connect Biopharma Sinks On Eczema Drug Readout

Connect Biopharma Holdings Limited 

CNTB -40.4%

 (Get Free Alerts for CNTB) announced positive topline results from the global Phase 2 clinical trial of CBP-201 administered subcutaneously to adult patients with moderate-to-severe atopic dermatitis.

The data showed that the trial met its primary efficacy endpoint, with statistically significant improvements in the percentage reduction in the Eczema Area and Severity Index score from baseline to Week 16. All three CBP-201 arms were statistically superior to placebo at Week 16. CBP-201 was also observed to have a favorable safety profile.

Lack of efficacy details limits comparison with existing treatments such as Sanofi 

SNY +0.44%

-Regeneron Pharmaceuticals, Inc.'s 

REGN +0.37%

 Dupixent and other biologics, potentially polarizing investors, SVB Leerink analyst Thomas Smith said.

https://www.benzinga.com/general/biotech/21/11/24190038/the-daily-biotech-pulse-connect-biopharma-sinks-on-eczema-drug-readout-enanta-pulls-plug-on-hbv-d